arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IN8BIO, INC.

INAB
$1.10 ▼ -0.04 (-3.91%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
7 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

IN8BIO, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -70.5% ↗
FCF / Share $-2.91 ↗
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-19.44M
↑ +36.1% —
FCF / Share Free cash flow per share
$-2.91
↑ +78.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
12
Cash Quality ↓
46

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters